Published in Ann Rheum Dis on January 12, 2012
Systemic sclerosis--challenges for clinical practice. Nat Rev Rheumatol (2012) 0.92
Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study. Clin Rheumatol (2013) 0.86
My approach to the treatment of scleroderma. Mayo Clin Proc (2013) 0.81
Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine (Baltimore) (2014) 0.79
Drug compliance in patients with systemic scleroderma. Clin Rheumatol (2012) 0.76
Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort. Ann Rheum Dis (2016) 0.75
Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. Semin Immunopathol (2015) 0.75
Lidocaine controls pain and allows safe wound bed preparation and debridement of digital ulcers in systemic sclerosis: a retrospective study. Clin Rheumatol (2016) 0.75
Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol (2017) 0.75
Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum (2003) 3.84
Autoantibodies in systemic sclerosis. Semin Arthritis Rheum (2005) 3.55
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis (2007) 2.60
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum (1996) 1.54
Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol (2010) 1.37
The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol (2008) 1.22
Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum (2009) 1.16
Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol (1996) 1.03
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Scleroderma. N Engl J Med (2009) 6.50
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol (2007) 6.13
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat Genet (2007) 5.93
Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol (2007) 5.16
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Differential roles of macrophages in diverse phases of skin repair. J Immunol (2010) 3.56
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum (2002) 3.55
Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol (2007) 3.51
TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature (2002) 3.21
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I. Nat Med (2013) 3.10
Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol (2004) 2.94
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis (2009) 2.76
E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions. EMBO J (2005) 2.72
T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med (2004) 2.58
Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades. Clin Exp Rheumatol (2012) 2.56
Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum (2009) 2.54
CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. Blood (2012) 2.43
Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity (2011) 2.39
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis (2006) 2.35
Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol (2006) 2.04
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis (2011) 1.99
Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med (2005) 1.93
Who was Pontormo's Halberdier? The evidence from pathology. Rheumatol Int (2011) 1.92
Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res (2004) 1.88
Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life. Chest (2007) 1.85
ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant (2005) 1.84
Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis (2010) 1.83
Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis (2010) 1.81
Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet J Rare Dis (2013) 1.78
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet (2011) 1.77
Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int (2010) 1.71
Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem (2002) 1.66
Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest (2006) 1.65
Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report. Ann Intern Med (2010) 1.65
Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol (2003) 1.63
Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum (2011) 1.56
Integrin alpha2beta1 is required for regulation of murine wound angiogenesis but is dispensable for reepithelialization. J Invest Dermatol (2006) 1.54
New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep (2007) 1.54
Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res (2002) 1.52
Interleukin-10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA. Eur J Immunol (2006) 1.51
High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med (2002) 1.50
Keratin 14 Cre transgenic mice authenticate keratin 14 as an oocyte-expressed protein. Genesis (2004) 1.48
Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol (2007) 1.46
Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology (Oxford) (2012) 1.45
Merkel cell polyomavirus DNA in persons without merkel cell carcinoma. Emerg Infect Dis (2009) 1.45
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol (2006) 1.43
Interrelation of immunity and tissue repair or regeneration. Semin Cell Dev Biol (2009) 1.42
Incidence of the pneumoconioses in the United Kingdom general population between 1997 and 2008. Respiration (2012) 1.41
Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) (2012) 1.41
A2b adenosine receptors in cardioprotection: timing is everything. J Mol Cell Cardiol (2010) 1.41
Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am J Pathol (2004) 1.39
Impaired epidermal wound healing in vivo upon inhibition or deletion of Rac1. J Cell Sci (2007) 1.39
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis (2006) 1.38
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis (2010) 1.38
Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res (2011) 1.36
Mast cell-specific Cre/loxP-mediated recombination in vivo. Transgenic Res (2007) 1.36
Keloids--clinical diagnosis, pathogenesis, and treatment options. J Dtsch Dermatol Ges (2004) 1.34
Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol (2004) 1.33
Multiple integrin-ligand interactions synergize in shear-resistant platelet adhesion at sites of arterial injury in vivo. Blood (2003) 1.32
Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosis. J Cell Mol Med (2013) 1.32
Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum (2005) 1.31
NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol (2004) 1.29
A novel automated indirect immunofluorescence autoantibody evaluation. Clin Rheumatol (2011) 1.27
Mechanical tension and integrin alpha 2 beta 1 regulate fibroblast functions. J Investig Dermatol Symp Proc (2006) 1.26
Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol (2014) 1.26
Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum (2007) 1.23
Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer (2002) 1.23
Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling. Hum Mol Genet (2006) 1.22
Wound-healing defect of CD18(-/-) mice due to a decrease in TGF-beta1 and myofibroblast differentiation. EMBO J (2005) 1.22
The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One (2013) 1.21
Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G. Basic Res Cardiol (2013) 1.21
Expression of integrin beta1 by fibroblasts is required for tissue repair in vivo. J Cell Sci (2010) 1.21
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood (2010) 1.21
Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol (2010) 1.18
Interactions of primary fibroblasts and keratinocytes with extracellular matrix proteins: contribution of alpha2beta1 integrin. J Cell Sci (2006) 1.17
Home telemonitoring in patients with chronic heart failure: a chance to improve patient care? Dtsch Arztebl Int (2010) 1.17
Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol (2010) 1.17
Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford) (2010) 1.16
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol (2004) 1.16
Dissecting the roles of endothelin, TGF-beta and GM-CSF on myofibroblast differentiation by keratinocytes. Thromb Haemost (2004) 1.15
Heterozygous deficiency of manganese superoxide dismutase results in severe lipid peroxidation and spontaneous apoptosis in murine myocardium in vivo. Free Radic Biol Med (2005) 1.14
Anxiety, sensory over-responsivity, and gastrointestinal problems in children with autism spectrum disorders. J Abnorm Child Psychol (2013) 1.14
Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med (2006) 1.14
Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum (2007) 1.14
Silicone granuloma of the face treated with minocycline. J Am Acad Dermatol (2005) 1.12
Cell-matrix interactions in dermal repair and scarring. Fibrogenesis Tissue Repair (2010) 1.11
Differential proteomic analysis distinguishes tissue repair biomarker signatures in wound exudates obtained from normal healing and chronic wounds. J Proteome Res (2010) 1.10
Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. Eur J Heart Fail (2008) 1.10
Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum (2004) 1.10
Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum (2004) 1.09
Accelerated wound closure in mice deficient for interleukin-10. Am J Pathol (2007) 1.09
Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. Am J Pathol (2006) 1.09
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther (2011) 1.09
Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta1. FEBS J (2005) 1.08
The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis (2007) 1.08